Compounds

Details Compounds Compounds

1998-09-24

2001-11-13

Carlson, Karen Cochrane (Department: 1653)

Chemistry: molecular biology and microbiology

Micro-organism, tissue cell culture or enzyme using process...

Recombinant dna technique included in method of making a...

C435S069100, C435S006120, C435S320100, C435S325000, C536S023100, C530S350000, C530S300000

Reexamination Certificate

active

06316219

ABSTRACT:

FIELD OF THE INVENTION
This invention relates to newly identified polypeptides and polynucleotides encoding such polypeptides, to their use in therapy and in identifying compounds which may be agonists, antagonists and/or inhibitors which are potentially useful in therapy, and to production of such polypeptides and polynucleotides.
BACKGROUND OF THE INVENTION
The drug discovery process is currently undergoing a fundamental revolution as it embraces ‘functional genomics’, that is, high throughput genome- or gene-based biology. This approach as a means to identify genes and gene products as therapeutic targets is rapidly superseding earlier approaches based on ‘positional cloning’. A phenotype, that is a biological function or genetic disease, would be identified and this would then be tracked back to the responsible gene, based on its genetic map position.
Functional genomics relies heavily on high-throughput DNA sequencing technologies and the various tools of bioinformatics to identify gene sequences of potential interest from the many molecular biology databases now available. There is a continuing need to identify and characterise further genes and their related polypeptides/proteins, as targets for drug discovery.
The ADP/ATP translocator, or adenine nucleotide translocator (ANT), is the most abundant mitochondrial protein. In its functional state, ANT is a homodimer of 30-kD subunits embedded asymmetrically in the inner mitochondrial membrane. The dimer forms a gated pore through which ATP is moved from the matrix into the cytoplasm. Three distinct human ANT cDNAs, ANT1, ANT2, and ANT3, have been cloned to date.
SUMMARY OF THE INVENTION
The present invention relates to ANT5, in particular ANT5 polypeptides and ANT5 polynucleotides, recombinant materials and methods for their production. In another aspect, the invention relates to methods for using such polypeptides and polynucleotides, including the treatment of congestive heart failure, ischaemic heart disease, cardiac arrhytmias, diastolic or systolic dysfunction, hypertrophic cardiomyopathy, stroke, hereinafter referred to as “the Diseases”, amongst others. In a further aspect, the invention relates to methods for identifying agonists and antagonists/inhibitors using the materials provided by the invention, and treating conditions associated with ANT5 imbalance with the identified compounds. In a still further aspect, the invention relates to diagnostic assays for detecting diseases associated with inappropriate ANT5 activity or levels.


REFERENCES:
Tuddenham et al., Nucleic Acids Research, vol. 22, No. 17, pp. 3511-3533, 1994.*
Del Arco et al. Molecular Cloning of Aralar, a New Member of the Mitochondrial Carrier Superfamily that Binds Calcium and is Present in Human Muscle and Brian. J. Biol. Chem. 273(36): 23327-23334, Sep. 4, 1998.*
Altschul, S.F. et al., “Basic Local Alignment Search Tool”, J. Mol. Biol., vol. 215, pp. 403-410 (1990).
Wilson, R. et al., “2.2 Mb of contiguous nucleotide sequence from chormosome III of C. elegans”, nature, vol. 368, pp. 32-38 (1994).
GenBank Accession #AA165922.
GenBank Accession #AA464939.
HGS EST #1251891.
HGS EST #1446423.
HGS EST #77196.
HGS EST #845411.
HGS EST #569377.
HGS EST #534741.

Affiliated with

Also associated with

Rating

Compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2586986